Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05086692
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:36.736393+00:00
Published At
2025-07-09T00:00:00+00:00
Record Updated At
2025-07-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-09"
protocolSection.identificationModule.nctId
"NCT05086692"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Unresectable Solid Tumor (protocolSection.conditionsModule.conditions)
  • Clear Cell Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung Cancer Squamous (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung Cancer Non-squamous (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (MSI-H) (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of Head and Neck (protocolSection.conditionsModule.conditions)
  • Cutaneous Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Pleural Mesothelioma (protocolSection.conditionsModule.conditions)
  • Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
  • MSI-H Solid Malignant Tumor (protocolSection.conditionsModule.conditions)
  • Cancer With A High Tumor Mutational Burden (protocolSection.conditionsModule.conditions)
  • Epithelial Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Gastroesophageal Junction (GEJ) Cancer (protocolSection.conditionsModule.conditions)
  • Acral Melanoma (protocolSection.conditionsModule.conditions)
  • Mucosal Melanoma (protocolSection.conditionsModule.conditions)
  • Cutaneous Melanoma (protocolSection.conditionsModule.conditions)
  • DMMR Solid Malignant Tumor (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • MSI-H Cancer (protocolSection.conditionsModule.conditions)
  • DMMR Cancer (protocolSection.conditionsModule.conditions)
  • Pancreas Adenocarcinoma (MSI-H) (protocolSection.conditionsModule.conditions)
  • Skin Cancer (protocolSection.conditionsModule.conditions)
  • Viral Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancers (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.